Market news

Detailed price information for Silo Pharma Inc (SILO-Q) from The Globe and Mail including charting and trades.

Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program

Patent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms develop

Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption ...

Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate   AI agent platform...

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Silo Pharma, Inc. (NASDAQ:SILO) is one of the best psychedelic stocks on our list. SILO reported on July 7 that its wholly owned subsidiary, QwikAgents, joined the NVIDIA Developer Program to support the advancement of its artificial intelligence agent integration […]

Silo Pharma's QwikAgents joins AMD's AI Developer Program, gaining cloud credits and tools to accelerate its AI agent platform.

Silo Pharma (NASDAQ:SMPL) announced that its wholly owned subsidiary, QwikAgents, has joined AMD’s AI Developer Program, giving the company access to AI development resources intended to support the expansion of its enterprise and consumer AI agent platform. Key Investor TakeawaysSilo Pharma (NASDAQ:SMPL) said QwikAgents has been accepted into the AMD AI Developer Program.

Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agentsSARASOTA, FLA., July 14, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced that its wholly owned

Investing.com - U.S. stock index futures edged lower on Friday as investors consolidated gains following Wall Street’s sharp relief rally, with easing crude oil prices and signs of a possible diplomatic breakthrough between Washington and Tehran helping stabilize broader market sentiment.

Silo Pharma Inc. (NASDAQ:SILO) shares dropped 22% on Friday after the company announced an at-the-market private placement that could raise up to $11.

Nvidia expands its life sciences AI ecosystem through a Certara partnership and QwikAgents' entry into its developer program.

NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing...